Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial
Latest Information Update: 03 Feb 2025
At a glance
- Drugs Bifikafusp alfa (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IMMUNOSABR2
- 30 Jan 2025 Status changed from active, no longer recruiting to discontinued. (This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.)
- 16 May 2024 Planned End Date changed from 1 Dec 2024 to 31 Jan 2025.
- 16 May 2024 Planned primary completion date changed from 1 Dec 2024 to 31 Jan 2025.